From: ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
Characteristic | No. of cases | No. of events | Two-year survival rate (± SE) in % | p-value |
---|---|---|---|---|
ADAM9 expression | Â | Â | Â | 0.026 |
low | 71 | 10 | 85.9 ± 4.1 |  |
high | 37 | 12 | 70.3 ± 7.5 |  |
pT-status | Â | Â | Â | < 0.001 |
pT1 | 54 | 2 | 96.3 ± 2.6 |  |
pT2/3/4 | 54 | 20 | 64.8 ± 6.5 |  |
Grading | Â | Â | Â | 0.001 |
G 1 | 11 | 0 | - | Â |
G 2 | 75 | 12 | 85.3 ± 4.1 |  |
G 3/4 | 22 | 10 | 54.5 ± 10.6 |  |
pN-status | Â | Â | Â | 0.001 |
pN0 | 51 | 10 | 80.4 ± 5.6 |  |
pN1+ | 12 | 8 | 41.7 ± 14.2 |  |
Residual tumour | Â | Â | Â | < 0.001 |
R0 | 78 | 10 | 87.2 ± 3.8 |  |
R1/2 | 15 | 8 | 46.7 ± 12.9 |  |
Metastasis | Â | Â | Â | < 0.001 |
M0 | 85 | 8 | 90.6 ± 3.2 |  |
M1 | 23 | 14 | 43.5 ± 10.3 |  |